AFX GER Week ended 07 Aug 2026

Weekly Investor Report

Carl Zeiss Meditec AG · Healthcare · Medical Instruments & Supplies

Open interactive chart View report data
Latest close 29.90 EUR
-2.0% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 10.8% above the Trend Line and sits at 30.9% of its 52-week range. The latest completed week returned -2.0%, after a -2.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100.

Setup score 39 out of 100
Latest Close 29.90 EUR 7 Aug 2026
1W Return -2.0% latest completed week
4W Return -2.3% short-term follow-through
12W Return 20.2% quarterly tape
Trend Breadth 1.9% 1 of 52 weeks active
Volume Ratio 1.9x vs 13-week average
What is working
  • The trend backdrop is active with a 1-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
  • Latest weekly return ranks in the weaker part of its sector group.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.0% Latest completed week; four-week move -2.3%. Indicator stack 5/85 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 51/100 26 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 10.8% above the Trend Line and sits at 30.9% of its 52-week range. The latest completed week returned -2.0%, after a -2.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.9x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1812-week average 0.16

12-week confirmation

Trend active1/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.18Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -2.3% over four weeks, 20.2% over 12 weeks, and -29.0% over one year. The current trend has remained active for 1 consecutive weeks.

Performance by holding period

1W-2.0%
4W-2.3%
12W20.2%
26W11.1%
52W-29.0%
Active trend streak1 weeks
Active weeks in one year1
Trend breadth1.9%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.66Latest activity-pressure read.
Pressure change60.3%Four-week change in activity pressure.
Leadership-17.15Latest relative-leadership reading.
RS change-15.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Dec 2025 Field coverage 94% Model confidence 75%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength62/100Blend of value, momentum, and quality. Underlying universe rank 39; rank 1 is best.
Value69/100Relative valuation strength. Underlying universe rank 32; rank 1 is best.
Quality65/100Profitability and accounting quality. Underlying universe rank 36; rank 1 is best.
Momentum11/100Medium-term price momentum. Underlying universe rank 90; rank 1 is best.
Growth34/100Revenue and earnings growth. Underlying universe rank 67; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework53/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
21.7x
Price divided by trailing earnings.
Price / sales
1.2x
Market value relative to trailing revenue.
EV / EBITDA
14.0x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
6.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
52.2%
Gross profit retained from each unit of revenue.
Operating margin
8.9%
Operating profit retained from revenue.
Free-cash-flow margin
8.0%
Free cash flow generated from revenue.
Return on invested capital
6.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
7.8%
Latest one-year revenue growth.
EPS growth
-21.0%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
40.1%
Latest one-year free-cash-flow growth.
Piotroski F-score
8/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
1.8%
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
1.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 26 relevant articles.

3 positive · 20 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-36.8%Distance below the 52-week high.
13-week volatility5.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+9.7%Week of 31 Jul.
Worst week-7.7%Week of 6 Mar.
Latest week-2.0%Week of 7 Aug.

Shape of recent returns

Strong gains8
Modest gains5
Flat weeks0
Modest losses7
Sharp losses6
Recent vol5.4%13-week weekly-return volatility.
Base vol5.8%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew4.0% / -4.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape34/100

Trend, activity pressure, participation, and risk combine to a 34/100 tape read.

 Indicator analysis35/100

Latest 12-week confirmation: trend 1/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.18; No reversal markers Factors52/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 59; Small Cap Core rank 62 SVQF53/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 178.5 of 375 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 26 relevant articles.

Carl Zeiss Meditec (XTRA:AFX) Refines Manufacturing Analytics, Is It A Bargain? Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 202629.90 EUR-2.0%26.99 EUR58.56 EUR1.66-17.151.9MOn
31 Jul 202630.50 EUR9.7%27.33 EUR58.95 EUR1.71-13.951.5MOff
24 Jul 202627.80 EUR-5.1%27.61 EUR59.37 EUR1.54-20.721.3MOff
17 Jul 202629.30 EUR-4.2%28.00 EUR59.83 EUR1.42-16.641.7MOff
10 Jul 202630.60 EUR6.5%28.33 EUR60.27 EUR1.03-14.801.4MOff
3 Jul 202628.74 EUR5.3%28.63 EUR60.70 EUR0.63-23.10288.6KOff
26 Jun 202627.30 EUR9.5%29.09 EUR61.12 EUR0.45-24.76204.0KOff
19 Jun 202624.94 EUR-0.2%29.63 EUR61.56 EUR0.38-33.19240.9KOff
12 Jun 202625.00 EUR-6.5%30.21 EUR62.04 EUR0.41-33.19118.5KOff
5 Jun 202626.74 EUR3.3%30.77 EUR62.56 EUR0.55-30.25179.8KOff
29 May 202625.88 EUR-1.5%31.26 EUR63.06 EUR0.58-34.51772.4KOff
22 May 202626.28 EUR5.6%31.83 EUR63.59 EUR0.58-33.96770.2KOff
15 May 202624.88 EUR-3.3%32.45 EUR64.08 EUR0.50-36.042.4MOff
8 May 202625.72 EUR-2.9%33.11 EUR64.60 EUR0.31-36.081.1MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context